May 2022: Trametinib takrorlanuvchi, past darajadagi seroz tuxumdon saratonini davolashning yangi standartiga aylanishi mumkin (Mekinist). The Lancet jurnalining 2022 yil fevral sonida chop etilgan tadqiqot natijalariga ko'ra, trametinib kimyoterapiyani ham, tamoksifen kabi antiestrogenlarni ham taxminan 52 foizga yengib, bemorlarning olti oylik rivojlanishsiz (saraton rivojlanmagan davr) omon qolishini qo'shdi.
Ilgari kimyoterapiya olgan tuxumdonlarning seroz o'smalari bo'lgan 260 ayolda Amerika Qo'shma Shtatlari va Buyuk Britaniya tadqiqotchilari kuniga bir marta og'iz orqali trametinibni beshta standart davolash rejimidan biri (kimyoterapiya yoki estrogenga qarshi dorilar) bilan solishtirishdi. Odatdagi davolanish bilan solishtirganda, trametinib ishtirokchilari 15 oydan keyin terapiyaga to'rt baravar yuqori javobni ko'rsatdilar. Trametinib 13 oy davomida kasallikning rivojlanishini sekinlashtirib, boshqa barcha davolash usullaridan ustun keldi (standart davolash uchun etti oyga nisbatan). Teri toshmasi, anemiya, yuqori qon bosimi, diareya va charchoq trametinib bilan davolashning potentsial xavfli salbiy ta'siridan biridir.
Low-grade serous ovaryan saraton is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
